IMUX - Immunic, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
+1.94 (+21.20%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close9.15
Bid11.10 x 1000
Ask11.18 x 900
Day's Range8.79 - 11.45
52 Week Range6.04 - 390.00
Avg. Volume239,226
Market Cap112.171M
Beta (3Y Monthly)2.29
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est50.00
  • PR Newswire17 days ago

    Immunic, Inc. to Participate in Upcoming May Conferences

    May 18-21: Digestive Disease Week® (DDW): Dr. Andreas Muehler, Chief Medical Officer of Immunic, will attend the DDW conference, being held at the San Diego Convention Center in San Diego. May 20-21: BioEquity Europe 2019: Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will present a company overview at 5:15 pm CEST on May 20 at the 20th Annual BioEquity Europe conference, being held at the Crowne Plaza Barcelona Fira Center Hotel in Barcelona, Spain.

  • PR Newswire27 days ago

    Immunic, Inc. Appoints Industry Veteran Tamara A. Seymour as Interim Chief Financial Officer

    SAN DIEGO, April 29, 2019 /PRNewswire/ -- Immunic, Inc. (IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Tamara A. Seymour, MBA, as its Interim Chief Financial Officer, effective April 26, 2019. "Ms. Seymour has a proven track record of guiding public and privately-held life sciences companies through their corporate life cycles, including capital raising, negotiating complex strategic transactions, setting and maintaining internal fiscal policy and driving revenue growth," stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.

  • We're sorry this is all we were able to find about this topic.